• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Tandem Diabetes Care launches Mobi mini automated insulin patch pump

February 13, 2024 By Sean Whooley

Tandem Diabetes Mobi insulin patch pump worn on hiker's leg
The Mobi miniature, durable automated insulin patch pump worn on a hiker’s leg. [Image courtesy of Tandem Diabetes Care]
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it kicked off the U.S. commercial launch of its Mobi insulin patch pump.

The San Diego-based company says Mobi, which is fully controllable from a mobile app, is the world’s smallest durable automated insulin delivery (AID) system. It received FDA clearance for people with diabetes ages six and up in July 2023.

Tandem said today that it began taking orders and shipping Mobi to eligible U.S. customers.

Mobi features a 200-unit insulin cartridge and an on-pump button to provide an alternative to phone control for insulin boluses. It comes in at less than half the size of the existing Tandem pump system, the t:slim X2 pump. Mobi can fit in a coin pocket, clip to clothing or go on the body with an adhesive sleeve.

The system features the same Control-IQ technology that powers the established t:slim X2. Control-IQ, an advanced hybrid closed-loop automated insulin delivery feature, predicts and helps prevent high and low blood sugar. It leads to improved time in range throughout the day and night.

“This tiny, wearable pump exceeded the expectations of users from an early access program, and we are thrilled to begin offering this exciting new technology to more people in the diabetes community,” said John Sheridan, Tanndem president and CEO. “With this launch, we are executing on our strategy to offer a differentiated portfolio of durable insulin pumps, providing choice, along with new options in wearability.”

Other features of the Tandem Mobi system

Mobi has compatibility with all existing Tandem-branded infusion sets manufactured by Convatec. That includes a new five-inch tubing option made just for Mobi. Infusion sets allow users to temporarily disconnect from pumps for convenience. The company offers more than 30 mix-and-match infusion site and tubing length combinations.

Tandem Mobi Insulin Pump with App
The Mobi automated insulin pump with the accompanying mobile app. [Image courtesy of Tandem Diabetes Care]
Users can control their Mobi pump through a compatible iPhone with a mobile iOS application. The system currently has compatibility with the Dexcom G6 continuous glucose monitor (CGM) and Tandem plans for more integration. First, the company expects G7 integration in the second quarter of this year, followed by the Abbott FreeStyle Libre 3.

Tandem recently made great strides on its CGM integration, becoming the first to pair an automated insulin delivery to Dexcom’s latest technology when it integrated G7 into the t:slim X2 in December. The company then became the first to add Abbott’s CGM to AID technology by integrating the FreeStyle Libre 2 Plus into the t:slim X2.

Additional Mobi features include water resistance to a depth of eight feet for up to two hours. The system has a physical button that allows users to deliver insulin boluses without their iPhone as well. Finally, the system uses modern wireless charging and has remote software update capabilities.

Tandem plans to process orders on a first-come, first-served basis. It targets users who meet specific eligibility requirements, including use of G6, with initial shipments.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Tandem Diabetes Care

IN CASE YOU MISSED IT

  • Medtrum introduces 300-unit tubeless insulin pump
  • Baxter reports positive smart infusion pump, EMR integration data
  • Dexcom to cease G6 CGM production next year, transition fully to G7
  • Modular Medical prices $4.7M public offering
  • Medtronic studies highlight MiniMed 780G’s cost-effectiveness

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS